$RNAZ News

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY

Transcode Therapeutics Files Prospecuts For Resale Of Up To 15,955,543 Shares By Selling Stockholders

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M

CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics shares are trading higher after the company announced the submission to the FDA of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with TTX-MC138 a

TransCode Therapeutics shares are trading higher after the company announced the submission to the FDA of an Investigational New Drug application amendment for a planned Phase 2a clinical trial with TTX-MC138 a

Transcode Therapeutics In Collaboration With Quantum Leap Healthcare Collaborative, Submitted An FDA Investigational New Drug Application Amendment For Planned Phase 2A Trial With Transcode's TTX-MC138

TransCode Therapeutics In Collaboration With Quantum Leap Announce Submission of IND Amendment For Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma

TransCode Therapeutics Reports Published Preclinical Data Showing TTX-MC138 Delivery To Glioblastoma Tumors And Improved Survival In Murine Models

TransCode Therapeutics Files For $150M Mixed Shelf Offering

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

TransCode Therapeutics And Quantum Leap Healthcare Launch Phase 2a Dose-Expansion Trial With TTX-MC138,